Using Proton MRS to Predict Response of SAHA treatment in Glioblastoma

使用质子 MRS 预测胶质母细胞瘤 SAHA 治疗的反应

基本信息

批准号：
8018516
负责人：
XIAOPING P HU
金额：
$ 32.7万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-04-01 至 2013-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8018516
关键词：
Adjuvant Therapy Adult Aftercare Alanine Animals Back Behavior Biochemical Biological Markers Biopsy Brain Neoplasms Cerebrospinal Fluid Cerebrum Classification Clinical Correlative Study Creatine Data Dose Drug Delivery Systems Early treatment Effectiveness Endogenous depression Epigenetic Process Evaluation Funding Glioblastoma Histone Deacetylase Inhibitor Histone Deacetylation Image Individual Inositol Institution Magnetic Resonance Spectroscopy Malignant Glioma Mass Spectrum Analysis Measures Mental Depression Metabolic Methods Modeling Modification Monitor Mood stabilizers Moods Motor Activity Neurons Newly Diagnosed Oncologist Operative Surgical Procedures Patient Self-Report Patients Phase Primary Brain Neoplasms Procedures Protons Quality of life Radiation therapy Rattus Recurrence Risk Social Interaction Staging Surveys Technology Testing Therapeutic Therapeutic Effect Time Tissues Tumor Suppressor Genes Vorinostat Zolinza alternative treatment base brain metabolism carcinogenesis clinical effect depressive symptoms disturbance in affect effective therapy experience imaging modality improved increased appetite inhibitor/antagonist innovation pre-clinical public health relevance research clinical testing response restoration standard of care temozolomide theories tool treatment duration tumor vector

项目摘要

DESCRIPTION (provided by applicant): Glioblastoma (GBM) is the most common primary brain tumor and is uniformly fatal despite aggressive surgical and adjuvant therapy. Since survival is short, it is critical to determine the value of therapy early during treatment. Improved early predictive assessment would allow neuro-oncologists to adjust or change treatment sooner to maximize use of the most effective therapy. During carcinogenesis, tumor suppressor genes can be silenced by aberrant histone deacetylation. This epigenetic modification has become an important target for tumor therapy. Suberoylanilide hydroxamic acid (SAHA) is an orally active, potent inhibitor of histone deacetylase (HDAC) activity. Clinical effects may include tumor control and cerebral biochemical alterations that may improve mood, correcting the depressive symptoms experienced by many of these patients. Clinical evaluation of SAHA in recurrent GBM is currently ongoing within the NCI-funded Adult Brain Tumor Consortium (ABTC) because of the promising preclinical results in malignant gliomas. In addition, a phase I evaluation in newly diagnosed GBM in combination with temozolomide and radiation therapy has just been opened by this group. The lack of reliable biomarkers to predict early response severely hampers the treatment of GBM tumor patients with HDAC inhibitors. Frequent histological evaluation is impractical for GBM due to the risks of invasive biopsies and unreliable endpoints. Another problem is that response to SAHA therapy is associated with tumor redifferentiation/cytostasis rather than tumor size reduction, limiting the use of traditional imaging methods. We propose to fill this void by optimizing an MRS method to pharmacodynamically assess biomarkers noninvasively and longitudinally. In this manner, we evaluate the efficacy of drug delivery and therapeutic effect early in the course of the treatment. Here our objective is to develop an MRS-based tool to aid clinicians in the early determination of the value of SAHA when administered to recurrent GBM patients treated with SAHA in combination with temozolomide, thereby identifying patients most likely to benefit. In addition, we will determine whether reduced inositol and NAA are reliable biomarkers of altered mood or depression in GBM patients, which may alleviated with SAHA treatment. Therefore, we plan to assess for potential improvement in the mood of recurrent GBM patients by correlating MRS data with a psychiatric evaluation. Establishing reliable MRS biomarkers to assess early response would clearly be of value in personalizing the management of glioblastoma patients by allowing clinicians to adjust the dose of SAHA treatment or seek alternative treatment. The ability to do this would be a highly innovative use of established technology (MRS) that would be readily implemented at most institutions. Importantly, our MRS-based tool will assess the restoration of normal brain metabolism, and indirectly monitor the subject's quality of life. PUBLIC HEALTH RELEVANCE: During carcinogenesis, tumor-suppressor genes can be silenced by aberrant histone deacetylation. This epigenetic modification has become an important target for tumor therapy. Vorinostat (SAHA, Zolinza; Merck & Co., Inc., Whitehouse Station, NJ) is an orally active, potent inhibitor of aberrant histone deacetylation activity that is currently being evaluated in glioblastoma patients. In this study, we will establish an important clinical tool to predict therapeutic response soon after treatment initiation. Our MRS- based tool will aid clinicians in early modification of SAHA treatment or in seeking alternative treatments in those with glioblastoma.

描述（由申请人提供）：胶质母细胞瘤（GBM）是最常见的原发性脑肿瘤，尽管具有侵略性手术和辅助治疗，但仍是致命的。由于生存时间很短，因此在治疗过程中确定治疗的价值至关重要。改进的早期预测评估将使神经肿瘤学家能够尽快调整或改变治疗，以最大程度地使用最有效的疗法。在癌变期间，抑制肿瘤基因可以通过异常的组蛋白脱乙酰化沉默。这种表观遗传修饰已成为肿瘤治疗的重要靶标。 suberoylanilide羟氨酸（SAHA）是一种口服活性的组蛋白脱乙酰基酶（HDAC）活性的抑制剂。临床影响可能包括控制肿瘤和脑生化改变，这些改变可能会改善情绪，从而纠正许多患者经历的抑郁症状。由于恶性神经胶质瘤的有希望的临床前结果，反复GBM中SAHA的临床评估目前正在进行中。此外，该组刚刚在新诊断的GBM中进行了I期评估，并结合替莫唑胺和放射治疗。缺乏可靠的生物标志物来预测早期反应会严重阻碍使用HDAC抑制剂的GBM肿瘤患者的治疗。由于侵入性活检和不可靠的终点的风险，频繁的组织学评估对于GBM是不切实际的。另一个问题是，对SAHA治疗的反应与肿瘤的重新分化/胞次症有关，而不是减少肿瘤大小，从而限制了传统成像方法的使用。我们建议通过优化一种MRS方法来填充该空隙，以非侵入性和纵向评估生物标志物。通过这种方式，我们在治疗过程中评估了药物输送和治疗作用的功效。在这里，我们的目标是开发一种基于MRS的工具，以帮助临床医生早期确定SAHA的价值，以与SAHA治疗的复发性GBM患者与Temozolomide结合使用，从而确定最有可能受益的患者。此外，我们还将确定减少的肌醇和NAA是否是GBM患者的情绪改变或抑郁症的可靠生物标志物，这可能会通过SAHA治疗缓解。因此，我们计划通过将MRS数据与精神病评估相关联，评估复发性GBM患者的情绪的潜在改善。通过允许临床医生调整SAHA治疗剂量或寻求替代治疗方法，建立可靠的生物标志物评估早期反应的人显然将具有价值。这样做的能力将是对已建立技术（MRS）的高度创新使用，这将在大多数机构中很容易实施。重要的是，我们的基于MRS的工具将评估正常脑代谢的恢复，并间接监测受试者的生活质量。公共卫生相关性：在癌变期间，肿瘤抑制基因可以通过异常的组蛋白脱乙酰化沉默。这种表观遗传修饰已成为肿瘤治疗的重要靶标。 Vorinostat（Saha，Zolinza; Merck＆Co.，Inc。，Whitehouse Station，NJ）是一种口服活跃的，有效的组蛋白脱乙酰基化活性，目前正在胶质母细胞瘤患者中进行评估。在这项研究中，我们将建立一个重要的临床工具来预测治疗开始后的治疗反应。我们的基于MRS的工具将帮助临床医生早期修改SAHA治疗或寻求胶质母细胞瘤患者的替代治疗。